KYTX
KYTX
US5019761049
Kyverna Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
169.827.000 142.604.000
19.1%
Operating Income -169.827.000 -142.604.000
19.1%
Pretax Income -161.307.000 -127.477.000
26.5%
Net Income Common Stockholders -161.307.000 -127.477.000
26.5%
-- --
--
-- --
--
ende